ArticleFrontiers in nutrition2026
A novel solid beverage RLMCR prevents obesity-related metabolic disorders through the gut-adipose axis.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global obesity epidemic and associated metabolic comorbidities have imposed an insurmountable strain on healthcare systems, underscoring the urgent need for simple, early interventions to curb obesity at its onset. To address this problem, we developed a novel solid beverage RLMCR (Chinese National Invention Patent No. ZL 202410541939.2) and proved its therapeutic effects on established obesity, yet its preventive potential and underlying mechanisms remain unelucidated. Purpose: This study aimed to further explore the preventive role of RLMCR on diet-induced obesity and elucidate its mechanism via the gut-adipose axis. Methods: Male C57BL/6J mice were given RLMCR throughout high-fat diet (HFD) feeding to assess its preventive efficacy against obesity. Post-intervention, key metabolic indices, including body weight, fat percentage, and glucose tolerance, were measured. Subsequently, energy expenditure was monitored, and cold tolerance assays, adipose histomorphology, and thermogenic gene expression analysis were conducted. To characterize the modulatory effects of RLMCR on gut microbiota, 16S rDNA sequencing and untargeted metabolomics analysis were performed. Fecal microbiota transplantation (FMT) was finally conducted to verify the mediating role of gut microbiota in the beneficial effects of RLMCR. Results: RLMCR markedly mitigated HFD-induced body weight gain and glucolipid metabolic disturbances, while significantly augmenting energy expenditure and cold tolerance. Besides, RLMCR facilitated white adipose tissue browning, as reflected by the emergence of multilocular adipocytes and the upregulation of core thermogenic genes including UCP1 and PGC-1α. Moreover, RLMCR effectively restored the HFD-induced gut microbial disruption and notably enriched the abundance of Conclusion: RLMCR effectively prevented HFD-induced obesity and metabolic dysfunction via gut microbiota-mediated adipose browning. These findings offer a novel preventive strategy for obesity and support the development of RLMCR-based anti-obesity products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.